Petros Pharmaceuticals, Inc. (PTPI) Stock Price & Analysis
Petros Pharmaceuticals, Inc. (PTPI) closed at USD 0 on Friday, October 23, 2026, up 0.00% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 0; the Oct 23, 2026 session ranged USD 0–0 on volume of 1,000 shares. Market capitalization is $84,744, with a 52-week range of USD 0–0.02 (PNK). Source: Nexqual, retrieved October 24, 2026 at 13:34 UTC.
Also available as compact Markdown for AI agents: nexqual.com/PTPI.md
Key facts (PTPI)
- Analysts: None.
- Total return with dividends: 1Y -90.0% vs S&P 500 +13.4%; 5Y -100.0% vs S&P 500 +76.9%.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (PTPI)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $7.8M | $6.0M | $5.8M | $5.1M | — | — |
| Gross profit | $6.2M | $3.7M | $4.2M | $3.9M | — | — |
| Operating income | -$18.0M | -$19.9M | -$13.6M | -$4.6M | -$4.6M | -$3.4M |
| Net income | -$9.0M | -$20.0M | -$8.2M | -$14.3M | $1.9M | -$3.2M |
| EPS (diluted) | -$206.25 | -$242.00 | -$158.75 | -$83.47 | -$1.56 | — |
| Free cash flow | — | — | — | -$2.6M | — | — |
| Gross margin | 79.5% | 61.8% | 72.0% | 76.3% | — | — |
| Operating margin | -231.1% | -332.4% | -233.9% | -90.5% | — | — |
| Net margin | -115.0% | -334.4% | -140.2% | -280.1% | — | — |
| Revenue growth | -18.3% | -23.3% | -2.8% | -12.2% | — | — |
| Cash + short-term investments | $23.8M | $9.4M | $13.3M | $1.7M | $5.1M | — |
| Total debt | — | $8.4M | $6.9M | — | — | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (PTPI)
P/B 0.1x · Earnings yield -3778.31%
P/E at fiscal year-ends: Dec 2025 0.1x.
Analysts (PTPI)
Consensus None.
Total return (dividends reinvested) (PTPI)
| 1Y (from 2025-10-24) | 5Y (from 2021-10-25) | |
|---|---|---|
| Total return | -90.0% | -100.0% |
| S&P 500 (SPY) | +13.4% | +76.9% |
| Per year | -90.1% | -91.5% |
| Volatility (annualized) | 198.8% | 164.1% |
| Max drawdown | -91.3% (Nov 2025→Oct 2026) | -100.0% (Dec 2021→Oct 2026) |
PTPI analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter | — | — | — | $0 | — |
| Next quarter (ends Mar 2025) | — | — | — | $0 | — |
| Current fiscal year (ends Dec 2024) | — | — | — | $0 | — |
| Next fiscal year | — | — | — | $0 | — |
Key Statistics (as of October 24, 2026 at 13:34 UTC)
| Price | USD 0 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 0 |
| Open | USD 0 |
| Day Range | USD 0 – 0 |
| 52-Week Range | USD 0 – 0.02 |
| Volume | 1,000 shares |
| Market Cap | $84,744 |
| Exchange | PNK |
Technical Analysis (PTPI)
Nexqual's technical model rates PTPI "SELL" based on 1 bullish and 5 bearish signals across 127 daily candles, as of October 24, 2026 at 13:34 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 35.05 (neutral) |
| vs SMA50 | Below (USD 0) |
| MACD | -0 (negative) |
Analyst Ratings (PTPI)
Wall Street analysts rate PTPI "None", per Nexqual as of October 24, 2026 at 13:34 UTC.
| Consensus Rating | None |
|---|
Earnings (PTPI)
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2024-09-30 | USD -13.25 vs est -7.25 ▼ miss |
| 2024-06-30 | USD -9.25 vs est -19.25 ▲ beat |
| 2024-03-31 | USD -42.25 vs est -36 ▼ miss |
| 2023-12-31 | USD -54.25 vs est -27.75 ▼ miss |
Source: Nexqual, October 24, 2026 at 13:34 UTC.
Financials & Fundamentals (PTPI)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -124.40% |
| Current Ratio | 1.25 |
| Total Cash | $3.49M |
| Total Debt | $0 |
Source: Nexqual, October 24, 2026 at 13:34 UTC.
Financial Health Score (PTPI)
Nexqual rates Petros Pharmaceuticals, Inc.'s overall financial health "Weak" across five dimensions, as of October 24, 2026 at 13:34 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Mixed — $3M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$7M (FY ended Dec 2025, 10-K) |
| Efficiency | Critical — ROE -124%, ROA -38.8% |
Ownership (PTPI)
| Insider Ownership | +25.59% |
|---|---|
| Institutional Ownership | +10.24% |
| Shares Outstanding | 42.37M |
| Float | 28.94M |
| Short % of Float | +0.77% |
Source: Nexqual, October 24, 2026 at 13:34 UTC.
From Petros Pharmaceuticals, Inc.'s Latest SEC 10-K Filing (filed 2026-04-15)
Key Strengths & Strategy (as disclosed to the SEC)
- Our proprietary technology is intended to enable pharmaceutical companies to efficiently navigate the FDA's Rx-to-OTC switch regulatory process and allow them to ensure their sponsored product complies with safety and efficacy standards.
- The SaaS component of our platform is being developed to assist companies in the operationalization and market access of their switch candidate, while the SaMD capabilities are being developed to enhance FDA regulatory review and approval, as well as consumer engagement.
- Petros is working towards the development of its proprietary SaaS and SaMD technology platform, moving away from reliance on manufacturing and supply channels as a source of significant revenue.
- We expect that as our proprietary technology is commercialized among our initial prospective customers, joint press releases and announcements will also have the potential to increase the pool of customers and lead to increased revenue and expanded utilization of our proprietary platform across the pharmaceutical industry.
Legal & Regulatory Risks (Item 1A, quoted)
- We may not receive the necessary authorizations to market our platform or any future new products, and any failure to timely do so may adversely affect our ability to grow our business.
- Any delay or failure to obtain necessary regulatory clearances or approvals could harm our business.
- Failure to comply with these rules, regulations, self-regulatory codes, circulars, and orders could result in significant civil and criminal penalties and costs and could have a material adverse impact on our business.
- Any change in the laws or regulations that govern the clearance and approval processes relating to our current, planned and future products could make it more difficult and costly to obtain clearance or approval for new products or to produce, market and distribute existing products.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| SUPN | Supernus Pharmaceuticals, Inc. | USD 40.7 | ▼ 3.26% |
| BHC | Bausch Health Companies Inc. | USD 6.44 | ▼ 0.77% |
| HCM | HUTCHMED (China) Limited | USD 14.36 | ▲ 0.56% |
| AMLX | Amylyx Pharmaceuticals, Inc. | USD 27.2 | ▼ 4.8% |
| RGC | Regencell Bioscience Holdings L | USD 7.67 | ▼ 21.81% |
| LQDA | Liquidia Corporation | USD 42.65 | ▲ 7.46% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 24, 2026 at 13:34 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt